Table 1.
Patient characteristics.
| Total (n = 82) | |
|---|---|
| Gender, n (%) | |
| Male | 51 (62) |
| Female | 31 (38) |
| Age, years (range) | |
| Median | 56 (23–71) |
| WHO performance status, n (%) | |
| 0 | 34 (42) |
| 1 | 37 (45) |
| 2 | 11 (13) |
| Prior lines of chemotherapy, n (%) | |
| 1 | 73 (89) |
| 2 | 9 (11) |
| Multifocal disease, n (%) | |
| Yes | 21 (26) |
| No | 61 (74) |
| Corticosteroid use, n (%)a | |
| Yes | 61 (74) |
| No | 21 (26) |
| Neurocognitive deficit, n (%) | |
| Yes | 43 (52) |
| No | 39 (48) |
| Bevacizumab combination therapy, n (%) | |
| Irinotecan | 67 (82) |
| Irinotecan and cetuximab | 15 (18) |
| Response, n (%) | |
| Response (CR + PR) | 29 (35) |
| Stable disease | 42 (51) |
| Progressive disease | 11 (14) |
| Median progression‐free survival, months | 5.3 |
| Responders | 10.9 |
| Non‐responders | 3.9 |
| Median overall survival, months | 8.2 |
| Responders | 13.8 |
| Non‐responders | 7.5 |
AbbreviationsCR, complete response; PR, partial response.
a
Prednisolone >10 mg.